Covidien Device Sales Grow 3% In Q1; Respiratory Biz Still Struggling
This article was originally published in The Gray Sheet
Executive Summary
Covidien's medical device revenues grew 3% to $1.6 billion in the firm's fiscal first quarter, with stronger contributions from its endomechanical and energy businesses offset by continuing weakness in sales of respiratory products